ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1383

Examining Cutaneous Disease Activity As an Outcome Measure for Clinical Trials in Dermatomyositis

Rebecca Gaffney1, Meera Tarazi2, Rui Feng3, David Pearson4 and Victoria P. Werth5, 1Dermatology, University of Pennsylvania, Philadelphia, PA, 2Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 3Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, 4Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, 5Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: clinical trials, dermatomyositis and quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The FDA encourages clearance of skin findings as a primary outcome of clinical trials for inflammatory skin conditions. However, some DM patients retain signs of inflammation and damage despite having an acceptable quality of life. The current standardized quality of life instruments, Skindex-29 and Dermatology Life Quality Index, are shown to correlate with Cutaneous Dermatomyositis Activity and Severity Index activity scores and have been validated for use in clinical trials. However, Skindex-29 and Dermatology Life Quality Index scores have not been examined in patients with mild disease (Cutaneous Dermatomyositis Activity and Severity Index activity score≤14), who may have an acceptable quality of life despite their cutaneous manifestations

Methods: This is a retrospective review of 171 patients enrolled in a prospective longitudinal database for DM. We evaluated the correlation of individual Skindex-29 and Dermatology Life Quality Index scores vs. the Cutaneous Dermatomyositis Activity and Severity Index activity scores in patients with DM skin disease. A linear model was fitted to determine the “Cutaneous Dermatomyositis Activity and Severity Index cut-off value”, which is the lowest Cutaneous Dermatomyositis Activity and Severity Index activity score at which the instrument correlates well with quality of life.

Results: The Dermatology Life Quality Index had the lowest Cutaneous Dermatomyositis Activity and Severity Index cut-off value at 3, compared to the other Skindex-29 subscales (Emotions, 9; Functioning, 7; Symptoms, 6). Below these Cutaneous Dermatomyositis Activity and Severity Index values, the Skindex-29 and Dermatology Life Quality Index are not shown to directly correlate with cutaneous disease activity, and further improvement in Cutaneous Dermatomyositis Activity and Severity Index activity score does not lead to further improvement in quality of life.

Conclusion:

Our findings suggest that quality of life is not directly affected by the minimal cutaneous disease activity below these Cutaneous Dermatomyositis Activity and Severity Index cut-off values and therefore total clearance of skin findings may be irrelevant as a meaningful outcome for patients. Additionally, the linear correlation of Cutaneous Dermatomyositis Activity and Severity Index with quality of life until the cut-off values suggests that changes in Cutaneous Dermatomyositis Activity and Severity Index scores are relevant over the spectrum of disease activity above these cut-offs. The results of this study should encourage design of trials that reach a meaningful endpoint in terms of quality of life for patients.


Disclosure: R. Gaffney, None; M. Tarazi, None; R. Feng, None; D. Pearson, None; V. P. Werth, CLASI, 4.

To cite this abstract in AMA style:

Gaffney R, Tarazi M, Feng R, Pearson D, Werth VP. Examining Cutaneous Disease Activity As an Outcome Measure for Clinical Trials in Dermatomyositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/examining-cutaneous-disease-activity-as-an-outcome-measure-for-clinical-trials-in-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/examining-cutaneous-disease-activity-as-an-outcome-measure-for-clinical-trials-in-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology